Apixaban, an orally available anticoagulant, inhibits SARS-CoV-2 replication and its major protease in a non-competitive way

OA Chaves, CQ Sacramento… - Journal of Molecular …, 2022 - academic.oup.com
The severe coronavirus disease 2019 (COVID-19) is associated with coagulopathy.
Anticoagulants, such as low-molecular-weight heparin, warfarin, thrombin inhibitors, and …
被引用次数：12 相关文章
[PDF] oup.com

[PDF][PDF] Apixaban, an orally available anticoagulant, inhibits SARS-CoV-2 replication and its major protease in a non-competitive way

OA Chaves, CQ Sacramento… - Journal of Molecular …, 2022 - academic.oup.com
The severe coronavirus disease 2019 (COVID-19) is associated with coagulopathy.
Anticoagulants, such as low-molecular-weight heparin, warfarin, thrombin inhibitors, and …
[PDF] fiocruz.br

[PDF][PDF] Apixaban, an orally available anticoagulant, inhibits SARS-CoV-2 replication and its major protease in a non-competitive way

OA Chaves, CQ Sacramento, N Fintelman-Rodrigues… - 2022 - arca.fiocruz.br
Dear Editor, The severe coronavirus disease 2019 (COVID-19) is associated with
coagulopathy. Anticoagulants, such as low-molecular-weight heparin, warfarin, thrombin …

Apixaban, an orally available anticoagulant, inhibits SARS-CoV-2 replication by targeting its major protease in a non-competitive way

OA Chaves, CQ Sacramento, N Fintelman-Rodrigues… - bioRxiv, 2021 - biorxiv.org
Anticoagulants are associated with clinical benefit against the 2019 coronavirus disease
(COVID-19), preventing COVID-19 associated coagulopathy. Blood coagulation factor Xa …

Apixaban, an orally available anticoagulant, inhibits SARS-CoV-2 replication and its major protease in a non-competitive way

OA Chaves, CQ Sacramento… - … of molecular cell …, 2022 - pubmed.ncbi.nlm.nih.gov
Apixaban, an orally available anticoagulant, inhibits SARS-CoV-2 replication and its major
protease in a non-competitive way Apixaban, an orally available anticoagulant, inhibits …
[HTML] nih.gov

[HTML][HTML] Apixaban, an orally available anticoagulant, inhibits SARS-CoV-2 replication and its major protease in a non-competitive way

OA Chaves, CQ Sacramento… - Journal of Molecular …, 2022 - ncbi.nlm.nih.gov
The severe coronavirus disease 2019 (COVID-19) is associated with coagulopathy.
Anticoagulants, such as low-molecular-weight heparin, warfarin, thrombin inhibitors, and …
[PDF] researchgate.net

[PDF][PDF] Apixaban, an orally available anticoagulant, inhibits SARS-CoV-2 replication by targeting its major protease in a non-competitive way 2

OA Chaves, CQ Sacramento, N Fintelman-Rodrigues… - drugs - researchgate.net
Anticoagulants are associated with clinical benefit against the 2019 coronavirus 32 disease
(COVID-19), preventing COVID-19 associated coagulopathy. Blood 33 coagulation factor Xa …
[HTML] europepmc.org

[HTML][HTML] Apixaban, an orally available anticoagulant, inhibits SARS-CoV-2 replication by targeting its major protease in a non-competitive way

A Chaves, CQ Sacramento, N Fintelman-Rodrigues… - 2021 - europepmc.org
Anticoagulants are associated with clinical benefit against the 2019 coronavirus disease
(COVID-19), preventing COVID-19 associated coagulopathy. Blood coagulation factor Xa …
[PDF] archive.org

[PDF][PDF] Apixaban, an orally available anticoagulant, inhibits SARS-CoV-2 replication and its major protease in a non-competitive way

OA Chaves, CQ Sacramento, N Fintelman-Rodrigues… - 2022 - scholar.archive.org
Dear Editor, The severe coronavirus disease 2019 (COVID-19) is associated with
coagulopathy. Anticoagulants, such as low-molecular-weight heparin, warfarin, thrombin …
[PDF] archive.org

[PDF][PDF] Apixaban, an orally available anticoagulant, inhibits SARS-CoV-2 replication by targeting its major protease in a non-competitive way 2

OA Chaves, CQ Sacramento, N Fintelman-Rodrigues… - drugs - scholar.archive.org
Anticoagulants are associated with clinical benefit against the 2019 coronavirus 32 disease
(COVID-19), preventing COVID-19 associated coagulopathy. Blood 33 coagulation factor Xa …